Glucocorticoids inhibit diastrophic dysplasia sulfate transporter activity in otosclerosis by interleukin-6

Laryngoscope

Volumn 116, Issue 9, 2006, Pages 1647-1650

  Imauchi, Yutaka ^a,b   Lombès, Marc ^c   Lainé, Pascale ^b   Sterkers, Olivier ^b,d   Ferrary, Evelyne ^b,d   Grayeli, Alexis Bozorg ^b,c,d  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d BEAUJON HOSPITAL   (France)

Author keywords

Bone remodeling; Cell culture; Cytokine; Steroids; Sulfate transport

Indexed keywords

CARRIER PROTEIN; DEXAMETHASONE; DIASTROPHIC DYSPLASIA SULFATE TRANSPORTER; GLUCOCORTICOID; INTERLEUKIN 6; MIFEPRISTONE; SULFATE; UNCLASSIFIED DRUG;

ARTICLE; BONE METABOLISM; BONE TURNOVER; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BINDING SITE; DYSPLASIA; EXTERNAL AUDITORY CANAL; HUMAN; HUMAN CELL; HUMAN TISSUE; OTOSCLEROSIS; PRIORITY JOURNAL; STAPES;

ANALYSIS OF VARIANCE; ANION TRANSPORT PROTEINS; CELLS, CULTURED; DEXAMETHASONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-6; MEMBRANE TRANSPORT PROTEINS; MIFEPRISTONE; OTOSCLEROSIS;

EID: 33748545944     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlg.0000231733.02481.59     Document Type: Article

References (14)

1. Donaldson JA, Snyder JM. Otosclerosis. In: Cummings CW, Frederickson JM, Harker LA, Krause CJ, Schuller DE, eds. Otolaryngology-Head Neck Surgery, 4th ed. St. Louis: Mosby-Year Book; 1993:2997-3016.
2. Schrader M, Poppendieck J, Weber B. Immunohistologic findings in otosclerosis. Ann Otol Rhinol Laryngol 1990;99:349-352.
3. Bodo M, Carinci P, Venti G, et al. Glycosaminoglycan metabolism and cytokine release in normal and otosclerotic human bone cells interleukin-1 treated. Connect Tissue Res 1997;36:231-240.
4. Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999;14:1061-1066.
5. Wallis GA. The importance of being sulfated. Curr Biol 1995;5:225-227.
6. Rossi A, Kaitila I, Wilcox WR, et al. Proteoglycan sulfation in cartilage and cell cultures from patients with sulfate dysplasia sulfate transporter chondrodysplasias: relationship to clinical severity and indications on the role of intracellular sulfate production. Mat Biol 1998;17:361-369.
7. Bozorg Grayeli A, Escoubet B, Bichara M, et al. Increased activity of diastrophic dysplasia sulfate transporter and its inhibition by sodium fluoride. Otol Neurotol 2003;24:854-862.
8. Bozorg Grayeli A, Sterkers O, Roulleau P, Elbaz P, Ferrary E, Silve C. Parathyroid hormone receptor expression and function in otosclerosis. Am J Physiol 1999;277:E1005-E1012.
9. Elgavish A, Meezan E. Sulfate transport in human lung fibroblasts (IMR-90): effect of pH and anions. Am J Physiol 1989;256:C486-494.
10. Satoh H, Susaki M, Shukunami C, Iyama K, Negoro T, Hiraki Y. Functional analysis of diastrophic dysplasia sulfate transporter. Its involvement in growth regulation of chondrocytes mediated by sulfated proteoglycans. J Biol Chem 1998;273:12307-12315.
11. Hueb MM, Goycoolea MV, Paparella MM. Otosclerosis: the university of Minnesota temporal bone collection. Otolaryngol Head Neck Surg 1991;105:396-405.
12. Bretlau P, Causse J, Causse J-B, Hansen HJ, Johnsen NJ, Saloman G. Otospongiosis and sodium fluoride, a blind experimental and clinical evaluation of the effect of sodium fluoride treatment in patients with otospongiosis. Ann Otol Rhinol Laryngol 1985;94:103-107.
13. Stanton R, Hobson G, Montgomery B, Moses P, Smith-Kirwin S, Funanage V. Glucocorticoids decrease interleukine-6 levels and induce mineralization of cultured osteogenic cells from children with fibrous dysplasia. J Bone Miner Res 1999;14:1104-1114.
14. Garcia J, Lopez A, de Cabo M, et al. Cyclosporin A decrease human macrophage interleukin-6 synthesis at post-transcriptional level. Mediators Inflamm 1999;8:253-259.